Target intelligence / Profile preview

Dedicator of cytokinesis protein 1 (DOCK1)

Target
DOCK1
Molecular classification
Enzyme (guanine nucleotide exchange factor / GEF), Signaling protein, Cytoskeletal regulator, Adapter protein-binding protein
01

Overview

Dedicator of cytokinesis protein 1 (DOCK1) is an evolutionarily conserved guanine nucleotide exchange factor (GEF) that catalyzes the activation of Rac1, a small Rho family GTPase important for regulating actin cytoskeleton remodeling. Distinctively, DOCK1 uses a DHR2 domain for GEF activity (rather than DH-PH domains) and functions as part of a bipartite complex with the adapter protein ELMO to coordinate cell migration, phagocytosis, cell-cell fusion, and cytoskeletal rearrangement, facilitating critical processes such as tissue development, immune cell function, and apoptotic cell clearance. Elevated DOCK1 expression associates with increased invasion and poorer prognosis in several cancers, highlighting its clinical relevance as both a biomarker and potential therapeutic target

Other names
DOCK180ced5 (C. elegans ortholog)180 kDa protein downstream of CRKDownstream of CrKdedicator of cytokinesis protein 1DOCK1ced5Dedicator Of Cytokinesis 1
02

Mechanism of action

Experimental approaches use small molecule inhibitors and RNAi to inhibit DOCK1 activity or expression, aiming to suppress DOCK1-mediated Rac activation, block cell motility, invasion, or sensitize cancer cells to apoptosis

03

Biological functions

Signal transductionCell migrationPhagocytosisCytoskeletal rearrangementCell adhesionCell proliferationMyoblast fusion and skeletal muscle developmentChemotaxisApoptotic cell clearance
04

Disease associations

Cancer (breast, ovarian, bladder, glioblastoma, AML - acute myeloid leukemia)Temporomandibular joint anomalyCell invasion/metastasisOther disorders of cell migration
05

Safety considerations

Since DOCK1 is widely involved in essential actin cytoskeletal dynamics and cell migration, targeting DOCK1 therapeutically could affect normal immune function, muscle development, and wound healingRisk of off-target effects on tissue development and repair processesPotential impact on normal apoptotic cell clearance mechanisms
06

Interacting drugs

No approved drugs directly target DOCK1 as of now
07

Biomarkers

High DOCK1 expression is a prognostic marker in some cancers (e.g., breast, ovarian, glioblastoma, and AML)May be used for patient stratification in clinical studies

Beyond the preview

Go deeper on Dedicator of cytokinesis protein 1 (DOCK1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dedicator of cytokinesis protein 1 (DOCK1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call